Eads & Heald Wealth Management Sells 30 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Eads & Heald Wealth Management lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 5,040 shares of the medical research company’s stock after selling 30 shares during the period. Thermo Fisher Scientific makes up approximately 1.3% of Eads & Heald Wealth Management’s portfolio, making the stock its 21st biggest holding. Eads & Heald Wealth Management’s holdings in Thermo Fisher Scientific were worth $2,675,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently modified their holdings of the company. Coppell Advisory Solutions LLC purchased a new position in shares of Thermo Fisher Scientific in the second quarter worth about $33,000. Live Oak Investment Partners purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $36,000. Tyler Stone Wealth Management purchased a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $37,000. Indiana Trust & Investment Management CO purchased a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $38,000. Finally, DHJJ Financial Advisors Ltd. purchased a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $38,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.3 %

TMO stock traded down $7.36 during midday trading on Monday, hitting $557.87. The company’s stock had a trading volume of 1,031,012 shares, compared to its average volume of 1,546,595. The company has a market cap of $212.94 billion, a PE ratio of 36.11, a P/E/G ratio of 2.38 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The firm’s 50-day moving average is $571.66 and its 200-day moving average is $526.14.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. The business had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.40 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research analyst reports. HSBC initiated coverage on Thermo Fisher Scientific in a report on Monday, December 18th. They set a “buy” rating and a $610.00 price target on the stock. Evercore ISI upped their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Citigroup assumed coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. The Goldman Sachs Group upped their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, TheStreet upgraded Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $601.56.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.